ScholarIQanswers from OpenAlex & ORCID
Paul Aisen
ResearcherPublications, citations & collaboration network
Paul Aisen is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Paul Aisen have?
ScholarIQindexed works
Paul Aisen has 414 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Paul Aisen have?
ScholarIQcitation count
Paul Aisen has 66,130 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Paul Aisen?
ScholarIQh-index
Paul Aisen has an h-index of 100 in OpenAlex.
What is the i10-index of Paul Aisen?
ScholarIQi10-index
Paul Aisen has an i10-index of 256 in OpenAlex.
What is the OpenAlex record for Paul Aisen?
ScholarIQopenalex
The OpenAlex for Paul Aisen is on the source record.
What are the most-cited papers on Paul Aisen?
ScholarIQmost cited works
Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease
Reisa A. Sperling, Paul Aisen, Laurel Beckett, David A. Bennett, Suzanne Craft, Anne M. Fagan, Takeshi Iwatsubo, Clifford R. Jack, Jeffrey Kaye, Thomas J. Montine, Denise C. Park, Eric M. Reiman, Christopher C. Rowe, Eric Siemers, Yaakov Stern, Kristine Yaffe, María C. Carrillo, Bill Thies, Marcelle Morrison‐Bogorad, Molly V. Wagster, Creighton H. Phelps
Lecanemab in Early Alzheimer’s Disease
Christopher H. van Dyck, Chad J. Swanson, Paul Aisen, Randall J. Bateman, Christopher Chen, Michelle Gee, Michio Kanekiyo, David Li, Larisa Reyderman, Sharon Cohen, Lutz Froelich, Sadao Katayama, Marwan Sabbagh, Bruno Vellas, David Watson, Shobha Dhadda, Michael C. Irizarry, Lynn D. Kramer, Takeshi Iwatsubo
Clinical and Biomarker Changes in Dominantly Inherited Alzheimer's Disease
Randall J. Bateman, Chengjie Xiong, Tammie L.S. Benzinger, Anne M. Fagan, Alison Goate, Nick C. Fox, Daniel S. Marcus, Nigel J. Cairns, Xianyun Xie, Tyler Blazey, David M. Holtzman, Anna Santacruz, Virginia Buckles, Angela Oliver, Krista L. Moulder, Paul Aisen, Bernardino Ghetti, William E. Klunk, Eric McDade, Ralph N. Martins, Colin L. Masters, Richard Mayeux, John M. Ringman, Martin N. Rossor, Peter R. Schofield, Reisa A. Sperling, Stephen Salloway, John C. Morris
Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria
Bruno Dubois, Harald Hampel, Howard Feldman, Philip Scheltens, Paul Aisen, Sandrine Andrieu, Hovagim Bakardjian, Habib Benali, Lars Bertram, Kaj Blennow, Karl Broich, Enrica Cavedo, Sebastian J. Crutch, Jean‐François Dartigues, Charles Duyckaerts, Stéphane Epelbaum, Giovanni B. Frisoni, Serge Gauthier, Rémy Genthon, Alida A. Gouw, Marie‐Odile Habert, David M. Holtzman, Miia Kivipelto, Simone Lista, José Luís Molinuevo, Sid E. O’Bryant, Gil D. Rabinovici, Christopher C. Rowe, Stephen Salloway, Lon S. Schneider, Reisa A. Sperling, Marc Teichmann, María C. Carrillo, Jeffrey L. Cummings, Cliff R Jack
Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease
Rachelle S. Doody, Ronald G. Thomas, Martin R. Farlow, Takeshi Iwatsubo, Bruno Vellas, Steven Joffe, Karl Kieburtz, Rema Raman, Xiaoying Sun, Paul Aisen, Eric Siemers, Hong Liu‐Seifert, Richard C. Mohs